Find Clinical Trials

188 Results

Protocol Code	Study Title	Active substance/Medical device	Study Phase	Therapeutic Area
CL1-64315-004	Phase I/II, international, multicentre, open-label, non-randomised, non-comparative, study evaluating the safety, tolerability and clinical activity…	S064315	Phase 1-2	Cancers
CL2-95011-001	A phase IIa efficacy and safety trial with intravenous S95011 in primary Sjögren’s Syndrome patients.…	S95011	Phase 2	Immune-Inflammatory Diseases
CL3-05167-005	Efficacy and safety of Atorvastatin + Perindopril Fixed-Dose Combination in adult patients with arterial hypertension…	ATORVASTATIN, PERINDOPRIL, S05167	Phase 3	Cardiovascular Diseases
CL1-95014-001	A Phase 2 Clinical Study of Pegaspargase in Patients With Newly Diagnosed, Untreated Acute Lymphoblastic…	PEGASPARGASE, S095014	Phase 2	Cancers
CL1-64315-003	A Phase I/II, open label, non-randomized study to evaluate safety, tolerability, pharmacokinetics and clinical activity…	S064315	Phase 1-2	Cancers
CL3-13001-002	Clinical Investigation to Determine the Accuracy and Benefit of Cardioskin™ in Patients With Known Atrial…	Cardioskin™	Phase 3	Cardiovascular Diseases
331602	Post Marketing Surveillance Study for ONIVYDE® in South Korea	Liposomal Irinotecan, S095013	Phase 4	Cancers
331501	Phase II Randomized Study of BAX2398 in Combination With 5-Fluorouracil and Calcium Levofolinate in Japanese…	Liposomal Irinotecan, S095013	Phase 2	Cancers
CL1-65487-002	Study of a New Intravenous Drug, Called S065487, in Patients With Acute Myeloid Leukemia, Non…	S065487	Phase 1	Cancers
CL1-64315-002	An International Phase Ib Multicentre Study to Characterize the Safety and Tolerability of Intravenously Administered…	S064315	Phase 1	Cancers
CL3-95008-002	Efficacy and safety of bumetanide oral liquid formulation in children aged from 2 to less…	BUMETANIDE, S095008	Phase 3	Neuropsychiatric Diseases
CL3-95008-001	Efficacy and safety of bumetanide oral liquid formulation in children and adolescents aged from 7…	BUMETANIDE, S095008	Phase 3	Neuropsychiatric Diseases
CL2-201086-002	Efficacy and safety of 3 doses of S201086/GLPG1972 administered orally once daily in patients with…	S201086	Phase 2	Rheumatology
Control-2	Efficacy of ivabradine in combination with beta-blockers vs up-titration of beta-blockers in daily practice	IVABRADINE, S016257	Phase 4	Cardiovascular Diseases
CL3-05153-008	A clinical study to test the safety and the efficacy of a single-pill combination of…	AMLODIPINE, ATORVASTATIN, PERINDOPRIL ARGININE, S005153	Phase 3	Cardiovascular Diseases
CL3-05682-109	Clinical non-inferiority study between Micronized purified flavonoid fraction 1000 mg, one chewable tablet per day…	MICRONISED PURIFIED FLAVONOID FRACTION, S005682	Phase 3	Cardiovascular Diseases
CL1-95010-001	Safety, Tolerability and Pharmacokinetics of S 95010 After Single Escalating Intravenous Doses in Young Healthy…	S095010	Phase 1	Cardiovascular Diseases
CL3-95005-006	An open-label, randomised, phase III Study cOmparing trifLuridine/tipiracil (S 95005) in combination with bevacizumab to…	TIPIRACIL, TRIFLURIDINE, S095005	Phase 3	Cancers
CL1-81694-003	Phase I/II trial of S 81694 administered intravenously in combination with paclitaxel to evaluate the…	S081694	Phase 1-2	Cancers
CL1-49076-002	Phase I/II study of S49076, a multi-target inhibitor of c-MET, AXL, FGFR in combination with…	S049076	Phase 1-2	Cancers
CL1-80881-002	INES - Phase Ib dose allocation study of oral administration of lucitanib given in combination…	LUCITANIB, S080881	Phase 1	Cancers
CL1-68587-001	A phase 1, open label, non-comparative, monocenter study to evaluate the safety and the ability…	UCART19, S068587	Phase 1	Cancers
IC4-95005-183-DEU	Prospective, Multicenter, Open-label Phase IV trial of Trifluridine/Tipiracil to Evaluate the Health-related Quality of Life…	TIPIRACIL, TRIFLURIDINE, S095005	Phase 4	Cancers
SC3-90049-001	Assessment of the acceptability of a sublingual formulation of piribedil (S90049), 10 to 30 mg…	PIRIBEDIL, S090049	Phase 3	Neuropsychiatric Diseases
SC2-90049-003	Effect of 3 doses (20, 40 and 60 mg) of a sublingual formulation of piribedil…	PIRIBEDIL, S090049	Phase 2	Neuropsychiatric Diseases